

# Enabling Equitable Access to Patients



Leveraging **THE POWER OF ONE**  
Ensuring affordable access to Lifesaving biosimilars,  
worldwide



Biocon Biologics is a unique, fully integrated leading global biosimilars player that is driven by an unwavering purpose to enable equitable access to high-quality, lifesaving biosimilars for patients globally.

Biocon Biologics is an end-to-end biosimilars enterprise with established capabilities in the development, manufacturing and commercialization of high-quality biosimilars. The company is leveraging cutting-edge science, advanced R&D skills, innovative tech platforms, global-scale manufacturing capabilities and internationally benchmarked quality and regulatory systems to address the global need for essential medicines to treat chronic diseases. Eight of its biosimilars, including insulins and antibodies, have been commercialized and are benefiting ~5.7 million patients annually in more than 100 countries.

As an industry pioneer, Biocon Biologics is among the first wave of companies to commercialize multiple biosimilars in the U.S., Europe and several other advanced and emerging market countries. These include Trastuzumab, Bevacizumab and Pegfilgrastim for cancer; Insulin Glargine, Insulin Aspart and recombinant human Insulin for diabetes, and Adalimumab and Etanercept for autoimmune diseases.



## BIOSIMILARS FRONTRUNNER

A frontrunner in the global biosimilars industry, Biocon Biologics has invested over USD 1 billion in building dedicated 'lab to market' capabilities for biosimilars. This has led to the creation of two state-of-the-art R&D facilities in India and three large-scale, globally compliant manufacturing facilities in India and Malaysia. The company has also invested in best-in-class quality processes and technology to meet the most stringent quality standards and successfully gain regulatory approvals in several jurisdictions, including U.S., EU, Australia, Canada and Japan. Biocon Biologics has achieved many global 'firsts,' including the industry's first approval of an interchangeable biosimilar for Insulin Glargine in the U.S. It is also the first globally to receive approvals for biosimilar Trastuzumab and biosimilar Pegfilgrastim from the U.S. Food and Drug Administration (FDA).

The company has been able to establish brand equity with patients, prescribers, payors and regulators through an impeccable track record of quality, safety, and reliability.

### BIOCON BIOLOGICS: QUICK FACTS



Bengaluru, India



Employees ~5,600

### FY2023 FINANCIAL HIGHLIGHTS



Revenue : INR 55,838 million (\$681 million)

### SIZE OF BIOSIMILARS PORTFOLIO: 20

#### COMMERCIALIZED BIOSIMILARS: 8

Pegfilgrastim	Aspart
Trastuzumab	rh-Insulin
Bevacizumab	Adalimumab*
Glargine U100	Etanercept*

Commercial reach: 100+ countries

Patients served globally: ~5.7 mn / year

Strong scientific talent and state-of-the-art  
R&D infrastructure

R&D sites: 2 (Bengaluru, Chennai)

Drug substance, drug product & devices  
manufacturing capabilities for insulins, mAbs

Manufacturing sites: 3  
(2 in Bengaluru, India; 1 in Johor, Malaysia)

cGMP approvals received: 85+

Bio-Manufacturing Capacity:  
Among Top 15 globally

*\*In-licensed products*



## THE 'POWER OF ONE'






To strengthen its leadership position in the global biosimilars industry, Biocon Biologics has acquired the global biosimilars business of its long-term partner Viatris for over USD 3 billion in cash and stock. This is a historic milestone in the company's value creation journey and brings it closer to patients, customers, and payors in several advanced and emerging market countries.

By combining the complementary capabilities and strengths of two long-term partners, it is leveraging THE POWER OF ONE with an aim to reduce healthcare inequities and transform healthcare, worldwide.



## COMPREHENSIVE PORTFOLIO

Biocon Biologics is well-positioned for future growth with its comprehensive portfolio of 20 biosimilars for diabetes, cancer, autoimmune diseases, ophthalmic conditions and bone health.

 Oncology	 Immunology	 Diabetes	 Ophthalmology	 Bone Health
Pegfilgrastim	Adalimumab <sup>1</sup>	Glargine U100	Aflibercept <sup>1</sup>	Denosumab
Trastuzumab	Ustekinumab	Aspart		
Bevacizumab	Etanercept <sup>1</sup>	Rh-Insulin		
Pertuzumab		Glargine U300		
Denosumab				

Seven more undisclosed assets under development

<sup>1</sup>In-licensed products



## STRONG ESG FOCUS

Environmental, Social and Governance (ESG) is at the core of Biocon Biologics' business purpose and responsibility. The company's philosophy of unconditional equity aims to ensure the well-being of patients, people, partners, customers, shareholders, communities and the ecosystem at large. By serving patients, protecting the environment and promoting business integrity, the company is taking 'sustainable action' every day, reinforcing its commitment to building an equitable and viable future.

## Biocon Biologics Limited

Biocon House, Semicon Park, Electronics City, Phase - II, Hosur Road, Bengaluru, Karnataka 560 100. India. T: **+91 80 6775 6775**.

Email: **Group.Comunications@biocon.com**

Website: **www.bioconbiologics.com**

Follow us at : 

Note: The information in this Fact Sheet is given as of the date mentioned, and Biocon Biologics does not assume any obligation to update the information on a frequent basis.

Last Updated: November, 2023

## Leadership Team

**Kiran Mazumdar-Shaw**  
Executive Chairperson

**Shreehas Tambe**  
CEO & Managing Director

**Kedar Upadhye**  
Chief Financial Officer

**Rhonda Duffy**  
Chief Operating Officer

**Matthew Erick**  
Chief Commercial Officer -  
Advanced Markets

**Susheel Umesh**  
Chief Commercial Officer -  
Emerging Markets

**Sandeep Nilkanth Athalye**  
Chief Development Officer

**Naveen Narayanan**  
Global Head of HR

**Paul Vazhayil Thomas**  
Global Head - Portfolio & Program Management

**Ganesh Reddy**  
Global Head of Manufacturing

**Kiran Kumar Gandhirajan**  
Site Head, Malaysia

**Michael Cutter**  
Global Head of Quality

**Anuj Goel**  
Global Head of R&D - CMC

**Seema Ahuja**  
Global Head - Corporate Brand &  
Head of Communications – EMS

**Stephanie Wasco**  
Head of Communications – Advanced Markets

**Stephen Fecho**  
Global Head - Supply Chain Management

**David Gibson**  
Global Head - Business Development

**Akhilesh Nand**  
General Counsel – Emerging Markets

**Stephen Manzano**  
General Counsel – Advanced Markets

**Mandar Ghatnekar**  
Global Head - IT & Digital Transformation

**Arlene Wolny**  
Global Head of Regulatory Affairs

**Uwe Gudat**  
Chief Medical Officer